
Tentarix: Innovating protein therapeutics through synthetic biology for enhanced bioactivity.
Tentarix Biotherapeutics was founded with the mission to innovate protein therapeutics through synthetic biology, aiming to create multifunctional biologics that offer enhanced bioactivity. The company focuses on developing advanced conditional multi-specifics, which are designed to target specific cells for improved treatment efficacy and reduced side effects. Tentarix's core vision is to overcome the challenges associated with the development of multi-specific therapeutics, including issues related to developability, complex biology, and desired pharmacology.
Notable figures affiliated with Tentarix include experts in synthetic biology and protein therapeutics, though specific names are not provided. The company has attracted significant interest from investors due to its pioneering approach in the biotherapeutics field. Key achievements include the development of precise therapies that promise better patient outcomes by minimizing side effects. Overall, Tentarix Biotherapeutics is making a substantial impact in the healthcare sector by pushing the boundaries of what is possible with protein-based treatments.
Companies similar to Tentarix Biotherapeutics include Adcentrx Therapeutics, GentiBio, Think Bioscience and Tunitas Therapeutics.
Tentarix Biotherapeutics was founded in 2020.
Tentarix Biotherapeutics' headquarters is located in San Diego, CA, US.
Tentarix Biotherapeutics' most recent funding round was for $35M (USD) in September 2023.
As of Sep 6, 2023, Tentarix Biotherapeutics has disclosed funding of $93M (USD). Undisclosed round amounts are excluded.
Tentarix Biotherapeutics has 35 employees as of Feb 4, 2024.
Tunitas Therapeutics